Fang XC,Wang XD,Bai CX,et al.COPD in China:the burden and importance of proper management[J].Chest,2011,139(4):920-929.
[2]
Barnes PJ.Immunology of asthma and chronic obstructive pulmonary disease[J].Nature Reviews Immunology,2008,8(3):183-192.
[3]
Walter RE,Wilk JB,Larson MG,et al.Systemic inflammation and COPD:the Framingham Heart Study[J].Chest,2008,133(1):19-25.
[4]
Global Initiative for Chronic Obstructive Lung Disease.Global Strategy for the Diagnosis,Management and Prevention of Chronic Obstructive Pulmonary Disease(updated 2014)[EB/OL].[2015-01-02].http://www.goldcopd.org/guidelines-global-strategy-for-dignosis-management.html.
[5]
Fabbri LM,Luppi F,Beghe B,et al.Update in chronic obstructive pulmonary disease 2005[J].American Journal of Respiratory and Critical Care Medicine,2006,173(10):1 056-1 065.
[6]
Miller AM,Liew FY.The IL-33/ST2pathway--A new therapeutic target in cardiovascular disease[J].Pharmacology&Therapeutics,2011,131(2):179-186.
[7]
Wu HX,Yang SF,Wu XJ,et al.Interleukin-33/ST2signaling promotes production of interleukin-6and interleukin-8in systemic inflammation in cigarette smokeinduced chronic obstructive pulmonary disease mice[J].Biochemical and Biophysical Research Communications,2014,450(1):110-116.
[8]
Joppa P,Petrasova D,Stancak B,et al.Systemic inflammation in patients with COPD and pulmonary hypertension[J].Chest,2006,130(2):326-333.
[9]
Shao D,Perros F,Caramori G,et al.Nuclear IL-33regulates soluble ST2receptor and IL-6expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension[J].Biochemical and Biophysical Research Communications,2014,451(1):8-14.
[10]
Xia J,Zhao J,Shang J,et al.Increased IL-33expression in chronic obstructive pulmonary disease[J].American Journal of Physiology Lung Cellular and Molecular Physiology,2015,308(7):L619-L627.
[11]
Carlomagno G,Messalli G,Melillo RM,et al.Serum soluble ST2and interleukin-33levels in patients with pulmonary arterial hypertension[J].International Journal of Cardiology,2013,168(2):1 545-1 547.
[12]
Martinez-Rumayor A,Camargo CA,Green SM,et al.Soluble ST2plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease[J].American Journal of Clinical Pathology,2008,130(4):578-584.
[13]
Tang Y,Guan Y,Liu Y,et al.The role of the serum IL-33/sST2axis and inflammatory cytokines in chronic obstructive pulmonary disease[J].Journal of interferon&cytokine research:the official journal of the International Society for Interferon and Cytokine Research,2014,34(3):162-168.
Dinarello CA.An IL-1family member requires caspase-1processing and signals through the ST2receptor[J].Immunity,2005,23(5):461-462.
[16]
Peinado VI,Barbera JA,Abate P,et al.Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease[J].American Journal of Respiratory and Critical Care Medicine,1999,159:1 605-1 611.
